Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro

PLoS One. 2021 Jan 7;16(1):e0244736. doi: 10.1371/journal.pone.0244736. eCollection 2021.

Abstract

Galectin-1 (gal-1) is a carbohydrate-binding lectin with important functions in angiogenesis, immune response, hemostasis and inflammation. Comparable functions are exerted by platelet factor 4 (CXCL4), a chemokine stored in the α-granules of platelets. Previously, gal-1 was found to activate platelets through integrin αIIbβ3. Both gal-1 and CXCL4 have high affinities for polysaccharides, and thus may mutually influence their functions. The aim of this study was to investigate a possible synergism of gal-1 and CXCL4 in platelet activation. Platelets were treated with increasing concentrations of gal-1, CXCL4 or both, and aggregation, integrin activation, P-selectin and phosphatidyl serine (PS) exposure were determined by light transmission aggregometry and by flow cytometry. To investigate the influence of cell surface sialic acid, platelets were treated with neuraminidase prior to stimulation. Gal-1 and CXCL4 were found to colocalize on the platelet surface. Stimulation with gal-1 led to integrin αIIbβ3 activation and to robust platelet aggregation, while CXCL4 weakly triggered aggregation and primarily induced P-selectin expression. Co-incubation of gal-1 and CXCL4 potentiated platelet aggregation compared with gal-1 alone. Whereas neither gal-1 and CXCL4 induced PS-exposure on platelets, prior removal of surface sialic acid strongly potentiated PS exposure. In addition, neuraminidase treatment increased the binding of gal-1 to platelets and lowered the activation threshold for gal-1. However, CXCL4 did not affect binding of gal-1 to platelets. Taken together, stimulation of platelets with gal-1 and CXCL4 led to distinct and complementary activation profiles, with additive rather than synergistic effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Galectin 1 / pharmacology*
  • Humans
  • N-Acetylneuraminic Acid / metabolism
  • Platelet Activation / drug effects*
  • Platelet Aggregation / drug effects
  • Platelet Factor 4 / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Signal Transduction / drug effects

Substances

  • Galectin 1
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Factor 4
  • N-Acetylneuraminic Acid

Grants and funding

This study was supported by Netherlands Foundation for Scientific Research (ZonMW) (www.zonmw.nl) in the form of a grant awarded to RRK (VIDI 016.126.358) and the Landsteiner Foundation for Blood Transfusion Research (LSBR) (www.lsbr.nl) in the form of a grant awarded to RRK (1638). CARIM School for Cardiovascular Diseases, Universiteit Maastricht financed the salary of AD (1198N), and the Maastricht Thrombosis Expertise Centre provided infrastructural support to MJEK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.